Ezgi Biltekin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ezgi Biltekin has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Metin Akay
Department of Biomedical Engineering, Cullen College of Engineering, University of Houston, Houston, TX 77204, USA
5 shared publications Bulent Ozpolat
Peggy and Charles Stephenson School of Biomedical Engineering, Gallogly College of Engineering, University of Oklahoma, Norman, OK, USA
4 shared publications- Bulent Ozpolat
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
4 shared publications - Mehrdad Bandegi
Department of Biomedical Engineering, Cullen College of Engineering, University of Houston, Houston, TX 77204, USA
3 shared publications Metin Akay
University of Houston , Houston
3 shared publicationsNermin Kahraman
Houston Methodist Research Institute , Houston
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by MDPI AG in Non-Coding RNA
- Vol. 12  (5) , 34
microRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer
MicroRNAs (miRNAs) are small non-coding RNAs that have emerged as critical regulators of gene expression and key cellular processes in cancer, including tumor cell proliferation, survival, metastasis, and both innate and adaptive immune responses within the tumor microenvironment. Through their ability to modulate immune cell development, differentiation, polarization, antigen presentation, cytokine signaling and immune checkpoint expression, miRNAs play a vital role in shaping immune responses and represent attractive therapeutic candidates for remodeling the tumor immune microenvironment. This review provides a comprehensive overview of the mechanisms through which miRNAs regulate anti-tumor immunity and contribute to immune evasion with particular emphasis on their role in modulating major immune checkpoint pathways, including PD-1/PD-L1, CTLA-4, LAG-3, TIM-3 and CD28-mediated signaling. We further examine the contribution of miRNAs to therapeutic resistance and discuss their potential integration with immune checkpoint blockade, chemotherapy, PARP inhibitors and targeted therapies to enhance antitumor efficacy and overcome treatment resistance. Recent advances in spatial transcriptomics and computational approaches have expanded our understanding of miRNA-mediated regulatory networks at single-cell and tissue levels and provide new insights into tumor–immune interactions. In addition, we evaluate the current progress in the clinical development of miRNA-based therapeutics, including miRNA mimics and inhibitors and discuss the major challenges associated with efficient delivery, off-target effects, immunogenicity and patient heterogeneity. Collectively, the evidence highlights the growing potential of miRNAs as diagnostic biomarkers, therapeutic targets and therapeutic tools in cancer immunotherapy. Continued advances in RNA therapeutics, delivery technologies and multi-omics approaches are expected to accelerate the clinical translation of miRNA-based strategies for personalized cancer therapy.
- 1 September 2026
- Published by MDPI AG in Non-Coding RNA
- Vol. 12  (5) , 34
Open AccessmicroRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer
MicroRNAs (miRNAs) are small non-coding RNAs that have emerged as critical regulators of gene expression and key cellular processes in cancer, including tumor cell proliferation, survival, metastasis, and both innate and adaptive immune responses within the tumor microenvironment. Through their ability to modulate immune cell development, differentiation, polarization, antigen presentation, cytokine signaling and immune checkpoint expression, miRNAs play a vital role in shaping immune responses and represent attractive therapeutic candidates for remodeling the tumor immune microenvironment. This review provides a comprehensive overview of the mechanisms through which miRNAs regulate anti-tumor immunity and contribute to immune evasion with particular emphasis on their role in modulating major immune checkpoint pathways, including PD-1/PD-L1, CTLA-4, LAG-3, TIM-3 and CD28-mediated signaling. We further examine the contribution of miRNAs to therapeutic resistance and discuss their potential integration with immune checkpoint blockade, chemotherapy, PARP inhibitors and targeted therapies to enhance antitumor efficacy and overcome treatment resistance. Recent advances in spatial transcriptomics and computational approaches have expanded our understanding of miRNA-mediated regulatory networks at single-cell and tissue levels and provide new insights into tumor–immune interactions. In addition, we evaluate the current progress in the clinical development of miRNA-based therapeutics, including miRNA mimics and inhibitors and discuss the major challenges associated with efficient delivery, off-target effects, immunogenicity and patient heterogeneity. Collectively, the evidence highlights the growing potential of miRNAs as diagnostic biomarkers, therapeutic targets and therapeutic tools in cancer immunotherapy. Continued advances in RNA therapeutics, delivery technologies and multi-omics approaches are expected to accelerate the clinical translation of miRNA-based strategies for personalized cancer therapy.
- Open Access
- 13 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (14) , 6238
Evaluating KRAS-Associated Responses to Sulfasalazine and 5-Fluorouracil in Colorectal Cancer Using Integrated 2D and PEGDA Microwell-Based 3D Tumor Models
Colorectal cancer (CRC) is a major cause of cancer-related mortality among adults younger than 50 years of age, and many tumors show incomplete response or develop resistance to 5-fluorouracil (5-FU)-based chemotherapy. Therefore, new therapeutic approaches that improve CRC sensitivity to existing chemotherapeutic agents are needed. KRAS-associated signaling contributes to CRC growth, metabolic adaptation and treatment resistance. In this study, we investigated whether sulfasalazine (SSZ), a U.S. Food and Drug Administration (FDA)-approved anti-inflammatory drug, could enhance the response of CRC cells to 5-FU and modulate KRAS/mitogen-activated protein kinase (MAPK)-associated signaling. Public dataset analysis using cBioPortal, Kaplan–Meier Plotter and DepMap showed that KRAS is commonly altered in CRC. The analysis also showed that higher KRAS expression was associated with shorter overall survival in 1061 CRC patients, while CRC cell-line models demonstrated KRAS dependency. In 2D cultures, both KRAS-mutant HCT116 and KRAS-wild-type RKO cells showed lower cell viability, reduced colony formation and decreased KRAS expression after SSZ treatment. In 3D cultures, exposure to SSZ reduced early spheroid formation, both as a single treatment and when combined with 5-FU. In established spheroids, SSZ-containing treatments affected cell viability, spheroid growth and morphology, with the most noticeable suppressive effect observed in RKO aggregates. SynergyFinder+ dose-matrix analysis identified dose ranges where SSZ and 5-FU showed additive-to-synergistic effects, leading us to select 600 μM SSZ with 25 μM 5-FU for further validation. Western blot results from PEGDA microwell-derived 3D spheroids showed that SSZ + 5-FU treatment reduced KRAS expression and affected KRAS/MAPK-related signaling. This effect was more pronounced in RKO cells, where downstream pathway suppression was stronger. The combination treatment also increased apoptosis-associated PARP cleavage. At the same time, it reduced Cyclin D1 and GPX4 protein levels and changed the expression of stemness-related markers, including ALDH1A3, CD44, and CD133. Together, these results support SSZ as a candidate repurposed adjuvant that may improve the response to 5-FU in CRC spheroid models and support the use of PEGDA microwell-based 3D platforms for testing combination therapy approaches.
- 13 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (14) , 6238
Open AccessEvaluating KRAS-Associated Responses to Sulfasalazine and 5-Fluorouracil in Colorectal Cancer Using Integrated 2D and PEGDA Microwell-Based 3D Tumor Models
Colorectal cancer (CRC) is a major cause of cancer-related mortality among adults younger than 50 years of age, and many tumors show incomplete response or develop resistance to 5-fluorouracil (5-FU)-based chemotherapy. Therefore, new therapeutic approaches that improve CRC sensitivity to existing chemotherapeutic agents are needed. KRAS-associated signaling contributes to CRC growth, metabolic adaptation and treatment resistance. In this study, we investigated whether sulfasalazine (SSZ), a U.S. Food and Drug Administration (FDA)-approved anti-inflammatory drug, could enhance the response of CRC cells to 5-FU and modulate KRAS/mitogen-activated protein kinase (MAPK)-associated signaling. Public dataset analysis using cBioPortal, Kaplan–Meier Plotter and DepMap showed that KRAS is commonly altered in CRC. The analysis also showed that higher KRAS expression was associated with shorter overall survival in 1061 CRC patients, while CRC cell-line models demonstrated KRAS dependency. In 2D cultures, both KRAS-mutant HCT116 and KRAS-wild-type RKO cells showed lower cell viability, reduced colony formation and decreased KRAS expression after SSZ treatment. In 3D cultures, exposure to SSZ reduced early spheroid formation, both as a single treatment and when combined with 5-FU. In established spheroids, SSZ-containing treatments affected cell viability, spheroid growth and morphology, with the most noticeable suppressive effect observed in RKO aggregates. SynergyFinder+ dose-matrix analysis identified dose ranges where SSZ and 5-FU showed additive-to-synergistic effects, leading us to select 600 μM SSZ with 25 μM 5-FU for further validation. Western blot results from PEGDA microwell-derived 3D spheroids showed that SSZ + 5-FU treatment reduced KRAS expression and affected KRAS/MAPK-related signaling. This effect was more pronounced in RKO cells, where downstream pathway suppression was stronger. The combination treatment also increased apoptosis-associated PARP cleavage. At the same time, it reduced Cyclin D1 and GPX4 protein levels and changed the expression of stemness-related markers, including ALDH1A3, CD44, and CD133. Together, these results support SSZ as a candidate repurposed adjuvant that may improve the response to 5-FU in CRC spheroid models and support the use of PEGDA microwell-based 3D platforms for testing combination therapy approaches.
- Open Access
Tumor-Suppressive microRNA Therapy Inhibits Growth of Glioblastoma Multiforme Xenografts
Glioblastoma multiforme (GBM) is defined by rapid progression, high invasiveness, and a poor prognosis, with a median survival of only ≅13 months despite current treatments. Its marked genetic heterogeneity, high mutational burden, and cancer stem cell population make GBM exceptionally difficult to treat, highlighting the urgent need for more effective, multitargeted therapies. Non-coding RNAs, particularly tumor suppressor microRNAs (miRNAs), have gained attention for suppressing key oncogenic processes that drive tumorigenesis, metastasis, and drug resistance, positioning them as promising tools for targeting multiple oncogenic pathways. We recently found that FOXM1/AXL-eEF2K collaboratively drive GBM cell proliferation, survival, and invasion through the formation of a signaling hub complex. In this study, we employed miRNA prediction algorithms to identify a specific miRNA, in vitro functional assays and in vivo GBM flank model to target GBM tumorigenesis by distrupting the FOXM1/AXL-eEF2K signaling hub. Our results indicated that FOXM1, AXL, and eEF2K are overexpressed in GBM patient tumors. To target the FOXM1/AXL-eEF2K signaling hub, we identified miR-449b-5p, miR-329-3p, and miR-518c as potential co-inhibitors of FOXM1/AXL-eEF2K and suppressors of cell proliferation, migration–invasion, and spheroid formation. Furthermore, the combination of miR-449b-5p, miR-329-3p, and miR-518c treatments with temozolomide led to synergistic enhancements in cell proliferation suppression and the induction of apoptosis and ferroptosis. More importantly, in vivo miR-329-3p treatment led to remarkable suppression of GBM tumor xenografts. These findings indicate that miR-329-3p-based tumor suppressor therapy may offer a multitargeted approach for GBM treatment.
Open AccessTumor-Suppressive microRNA Therapy Inhibits Growth of Glioblastoma Multiforme Xenografts
Glioblastoma multiforme (GBM) is defined by rapid progression, high invasiveness, and a poor prognosis, with a median survival of only ≅13 months despite current treatments. Its marked genetic heterogeneity, high mutational burden, and cancer stem cell population make GBM exceptionally difficult to treat, highlighting the urgent need for more effective, multitargeted therapies. Non-coding RNAs, particularly tumor suppressor microRNAs (miRNAs), have gained attention for suppressing key oncogenic processes that drive tumorigenesis, metastasis, and drug resistance, positioning them as promising tools for targeting multiple oncogenic pathways. We recently found that FOXM1/AXL-eEF2K collaboratively drive GBM cell proliferation, survival, and invasion through the formation of a signaling hub complex. In this study, we employed miRNA prediction algorithms to identify a specific miRNA, in vitro functional assays and in vivo GBM flank model to target GBM tumorigenesis by distrupting the FOXM1/AXL-eEF2K signaling hub. Our results indicated that FOXM1, AXL, and eEF2K are overexpressed in GBM patient tumors. To target the FOXM1/AXL-eEF2K signaling hub, we identified miR-449b-5p, miR-329-3p, and miR-518c as potential co-inhibitors of FOXM1/AXL-eEF2K and suppressors of cell proliferation, migration–invasion, and spheroid formation. Furthermore, the combination of miR-449b-5p, miR-329-3p, and miR-518c treatments with temozolomide led to synergistic enhancements in cell proliferation suppression and the induction of apoptosis and ferroptosis. More importantly, in vivo miR-329-3p treatment led to remarkable suppression of GBM tumor xenografts. These findings indicate that miR-329-3p-based tumor suppressor therapy may offer a multitargeted approach for GBM treatment.
- Open Access
- 30 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Open Journal of Engineering in Medicine and Biology
- Vol. 7, 146-157
MicroRNA-873 Suppresses Viability and Invasion of Colorectal Cancer Through KRAS/MAPK Signaling and Sensitizes Tumor Spheroids to 5-Fluorouracil in a 3D Microwell Model
Colorectal cancer (CRC) ranks third in incidence among all malignancies and is highly lethal in advanced stages. Combination chemotherapy regimens based on 5-fluorouracil (5-FU) remain the mainstay of colorectal cancer treatment alongside surgical resection. Even though new treatment modalities are emerging, many are either ineffective against KRAS-mutant tumors or prone to therapy resistance. Therefore, there is a critical need for new targeted therapies that may overcome the KRAS-driven chemoresistance and enhance the effect of chemotherapy. MicroRNAs can modulate several oncogenic pathways at once and can strengthen chemotherapy. In this study, we identified miR-873 as a potential chemosensitizer that modulates KRAS/MAPK signaling in CRC. We found that KRAS is overexpressed in metastatic versus primary tissues and in a large CRC patient cohort (n = 1,061), high KRAS expression was associated with worse overall survival (HR = 1.27; 95% CI, 1.04–1.56; log-rank p = 0.018). In vitro inhibition of KRAS by siRNA reduced clonogenic growth (HCT116, p = 0.0023; RKO, p = 0.0018) and invasion (p ≤ 0.0001). In silico prediction (TargetScan/miRWalk) analyses showed a conserved binding site between miR-873 and KRAS 3′UTR. Consistent with this prediction, miR-873 mimic transfection reduced KRAS protein expression and phenocopied KRAS knockdown by suppressing colony formation (p ≤ 0.0021) and invasion (p ≤ 0.0001) in KRAS-mutant HCT116 and KRAS-wild-type RKO cells. Dose-matrix screening and SynergyFinder+ analysis revealed synergistic inhibition of spheroid viability with miR-873 + 5-FU, including a low-dose pair (25 nM miR-873 + 12.5 μM 5-FU) showing positive synergy across ZIP/HSA/Bliss/Loewe models. In a poly(ethylene glycol)diacrylate(PEGDA) microwell 3D platform that generates uniform, size-controlled CRC spheroids, this combination produced the strongest suppression of spheroid expansion (day-5/day-3 area: HCT116, 0.61 ± 0.18 vs control, 2.08 ± 0.49; RKO, 0.66 ± 0.04 vs control, 2.08 ± 0.31) and reduced the live-cell fraction to ∼41% in both lines. Moreover, western blot analysis showed decreased KRAS and MAPK pathway activity (reduced p-ERK and context-dependent p-MEK), reduced Cyclin D1, and increased apoptotic readouts (cleaved PARP and a Bax/Bcl-2 shift). Together, these results position miR-873 treatment as a potential targeting approach to suppress KRAS/MAPK signaling and sensitize CRC to 5-FU and validate our PEGDA microwell 3D platform as a practical, translational testbed for miRNA–chemotherapy combinations.
- 30 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Open Journal of Engineering in Medicine and Biology
- Vol. 7, 146-157
Open AccessMicroRNA-873 Suppresses Viability and Invasion of Colorectal Cancer Through KRAS/MAPK Signaling and Sensitizes Tumor Spheroids to 5-Fluorouracil in a 3D Microwell Model
Colorectal cancer (CRC) ranks third in incidence among all malignancies and is highly lethal in advanced stages. Combination chemotherapy regimens based on 5-fluorouracil (5-FU) remain the mainstay of colorectal cancer treatment alongside surgical resection. Even though new treatment modalities are emerging, many are either ineffective against KRAS-mutant tumors or prone to therapy resistance. Therefore, there is a critical need for new targeted therapies that may overcome the KRAS-driven chemoresistance and enhance the effect of chemotherapy. MicroRNAs can modulate several oncogenic pathways at once and can strengthen chemotherapy. In this study, we identified miR-873 as a potential chemosensitizer that modulates KRAS/MAPK signaling in CRC. We found that KRAS is overexpressed in metastatic versus primary tissues and in a large CRC patient cohort (n = 1,061), high KRAS expression was associated with worse overall survival (HR = 1.27; 95% CI, 1.04–1.56; log-rank p = 0.018). In vitro inhibition of KRAS by siRNA reduced clonogenic growth (HCT116, p = 0.0023; RKO, p = 0.0018) and invasion (p ≤ 0.0001). In silico prediction (TargetScan/miRWalk) analyses showed a conserved binding site between miR-873 and KRAS 3′UTR. Consistent with this prediction, miR-873 mimic transfection reduced KRAS protein expression and phenocopied KRAS knockdown by suppressing colony formation (p ≤ 0.0021) and invasion (p ≤ 0.0001) in KRAS-mutant HCT116 and KRAS-wild-type RKO cells. Dose-matrix screening and SynergyFinder+ analysis revealed synergistic inhibition of spheroid viability with miR-873 + 5-FU, including a low-dose pair (25 nM miR-873 + 12.5 μM 5-FU) showing positive synergy across ZIP/HSA/Bliss/Loewe models. In a poly(ethylene glycol)diacrylate(PEGDA) microwell 3D platform that generates uniform, size-controlled CRC spheroids, this combination produced the strongest suppression of spheroid expansion (day-5/day-3 area: HCT116, 0.61 ± 0.18 vs control, 2.08 ± 0.49; RKO, 0.66 ± 0.04 vs control, 2.08 ± 0.31) and reduced the live-cell fraction to ∼41% in both lines. Moreover, western blot analysis showed decreased KRAS and MAPK pathway activity (reduced p-ERK and context-dependent p-MEK), reduced Cyclin D1, and increased apoptotic readouts (cleaved PARP and a Bax/Bcl-2 shift). Together, these results position miR-873 treatment as a potential targeting approach to suppress KRAS/MAPK signaling and sensitize CRC to 5-FU and validate our PEGDA microwell 3D platform as a practical, translational testbed for miRNA–chemotherapy combinations.
- 1 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27  (Supplement) , v346
EXTH-36. Novel miRNA Based Tumor Suppressive Therapy In Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is a WHO grade IV glioma, that is characterized by its aggressive growth, high invasiveness, and poor clinical outcomes. Despite the current standard of care treatments -surgical resection, radiotherapy, and first-line chemotherapy with temozolomide- the median survival remains only 12–17 months, with a 5-year survival rate of approximately 7%. GBM tumors defined by significant molecular heterogeneity, elevated mutational burden, and presence of therapy-resistant cancer stem cells. Thus, there is an urgent need for innovative, multi-targeted therapeutic strategies. Recent research highlighted the potential of non-coding RNAs, particularly microRNAs, to regulate multiple oncogenic pathways simultaneously. Our analyses of the Rembrandt patient dataset identified three significantly overexpressed key oncogenic signaling molecules (eEF2K, AXL, and FOXM1) in GBM patient tumors and in GBM cell lines. To therapeutically target these drivers, we utilized miRNA-Target gene prediction algorithms and identified three candidate miRNAs with predicted direct binding affinity. We demonstrated, for the first time, that miR-329-5p, miR-449-5p and miR-518c negatively regulate eEF2K, AXL, FOXM1 oncogenes and effectively downregulate their expression. Furthermore, we performed colony formation, wound healing(scratch), invasion(transwell) and 3D spheroid formation assay to evaluate the effects of the candidate miRNAs on cellular proliferation, metastatic potential, and stemness characteristics of GBM. Simultaneously or combined targeting of eEF2K, AXL, FOXM1 oncogenic molecules by each of the miRNAs(miR-329-5p, miR-449-5p, or miR-518c) led to suppression of GBM cell proliferation, migration, invasion, spheroid formation and induced both apoptosis and ferroptosis. Importantly, the combination of these miRNAs with temozolomide produced synergistic anti-proliferative effects in vitro. Moreover, in vivo once a week systemic treatment with miR-329-3p(0.15 mg/kg) incorporated in single lipid nanoparticle significantly suppressed eEF2K, AXL, FOXM1 expression and tumor growth in LN229 GBM xenograft tumor model in mice. These findings support the therapeutic potential of miRNA-based interventions as a multi-targeting strategy, either as monotherapy or in combination with current chemotherapeutics, for more effective management of glioblastoma.
- 1 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27  (Supplement) , v346
EXTH-36. Novel miRNA Based Tumor Suppressive Therapy In Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is a WHO grade IV glioma, that is characterized by its aggressive growth, high invasiveness, and poor clinical outcomes. Despite the current standard of care treatments -surgical resection, radiotherapy, and first-line chemotherapy with temozolomide- the median survival remains only 12–17 months, with a 5-year survival rate of approximately 7%. GBM tumors defined by significant molecular heterogeneity, elevated mutational burden, and presence of therapy-resistant cancer stem cells. Thus, there is an urgent need for innovative, multi-targeted therapeutic strategies. Recent research highlighted the potential of non-coding RNAs, particularly microRNAs, to regulate multiple oncogenic pathways simultaneously. Our analyses of the Rembrandt patient dataset identified three significantly overexpressed key oncogenic signaling molecules (eEF2K, AXL, and FOXM1) in GBM patient tumors and in GBM cell lines. To therapeutically target these drivers, we utilized miRNA-Target gene prediction algorithms and identified three candidate miRNAs with predicted direct binding affinity. We demonstrated, for the first time, that miR-329-5p, miR-449-5p and miR-518c negatively regulate eEF2K, AXL, FOXM1 oncogenes and effectively downregulate their expression. Furthermore, we performed colony formation, wound healing(scratch), invasion(transwell) and 3D spheroid formation assay to evaluate the effects of the candidate miRNAs on cellular proliferation, metastatic potential, and stemness characteristics of GBM. Simultaneously or combined targeting of eEF2K, AXL, FOXM1 oncogenic molecules by each of the miRNAs(miR-329-5p, miR-449-5p, or miR-518c) led to suppression of GBM cell proliferation, migration, invasion, spheroid formation and induced both apoptosis and ferroptosis. Importantly, the combination of these miRNAs with temozolomide produced synergistic anti-proliferative effects in vitro. Moreover, in vivo once a week systemic treatment with miR-329-3p(0.15 mg/kg) incorporated in single lipid nanoparticle significantly suppressed eEF2K, AXL, FOXM1 expression and tumor growth in LN229 GBM xenograft tumor model in mice. These findings support the therapeutic potential of miRNA-based interventions as a multi-targeting strategy, either as monotherapy or in combination with current chemotherapeutics, for more effective management of glioblastoma.
- Open Access
- 15 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26  (14) , 6792
Inhibition of FOXM1 Leads to Suppression of Cell Proliferation, Migration, and Invasion Through AXL/eEF2 Kinase Signaling and Induces Apoptosis and Ferroptosis in GBM Cells
Glioblastoma multiforme (GBM) is an aggressive and molecularly heterogeneous brain cancer with a poor prognosis. Despite advancements in standard-of-care therapies, including surgery, radiotherapy, and temozolomide (TMZ), the median survival remains approximately 15 months, with a 5-year survival rate of less than 10%. We and others have demonstrated that FOXM1 is a critical oncogenic driver of GBM cell proliferation. However, the role of FOXM1 and its interaction with other oncogenic signaling pathways in GBM remains incompletely understood. In this study, we identified FOXM1, AXL, and eEF2K as highly upregulated oncogenes in GBM patient tumors. We demonstrated, for the first time, that FOXM1 directly interacts with AXL and eEF2K, regulating their expression and promoting GBM cell proliferation, migration, and invasion. Knockdown of these genes disrupted cell proliferation, spheroid formation, migration, and invasion, and induced apoptosis and ferroptosis. Additionally, inhibiting the FOXM1–AXL/eEF2K signaling axis sensitized GBM cells to TMZ, further enhancing apoptotic and ferroptotic responses. These findings highlight the critical role of the FOXM1–AXL/eEF2K signaling pathway in GBM progression and suggest that targeting this axis may offer a novel multitargeted therapeutic strategy in GBM.
- 15 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26  (14) , 6792
Open AccessInhibition of FOXM1 Leads to Suppression of Cell Proliferation, Migration, and Invasion Through AXL/eEF2 Kinase Signaling and Induces Apoptosis and Ferroptosis in GBM Cells
Glioblastoma multiforme (GBM) is an aggressive and molecularly heterogeneous brain cancer with a poor prognosis. Despite advancements in standard-of-care therapies, including surgery, radiotherapy, and temozolomide (TMZ), the median survival remains approximately 15 months, with a 5-year survival rate of less than 10%. We and others have demonstrated that FOXM1 is a critical oncogenic driver of GBM cell proliferation. However, the role of FOXM1 and its interaction with other oncogenic signaling pathways in GBM remains incompletely understood. In this study, we identified FOXM1, AXL, and eEF2K as highly upregulated oncogenes in GBM patient tumors. We demonstrated, for the first time, that FOXM1 directly interacts with AXL and eEF2K, regulating their expression and promoting GBM cell proliferation, migration, and invasion. Knockdown of these genes disrupted cell proliferation, spheroid formation, migration, and invasion, and induced apoptosis and ferroptosis. Additionally, inhibiting the FOXM1–AXL/eEF2K signaling axis sensitized GBM cells to TMZ, further enhancing apoptotic and ferroptotic responses. These findings highlight the critical role of the FOXM1–AXL/eEF2K signaling pathway in GBM progression and suggest that targeting this axis may offer a novel multitargeted therapeutic strategy in GBM.
- Open Access
- 10 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26  (12) , 5533
MiR 329/449 Suppresses Cell Proliferation, Migration and Synergistically Sensitizes GBM to TMZ by Inhibiting Src/FAK, NF-kB, and Cyclin D1 Activity
Glioblastoma Multiforme (GBM) is one of the most common brain tumors and is associated with aggressive tumor characteristics and extremely poor patient survival. The median survival time for GBM patients is around 12–15 months. Temozolomide (TMZ) is a key chemotherapeutic drug used in the treatment of GBM. However, at least 50% of GBM patients do not respond to TMZ, necessitating the identification of novel therapeutic strategies sensitizing patients to TMZ. In this study, we aimed to investigate the effects of two different tumor suppressor microRNAs (miR-329 and miR-449b) on cell proliferation and migration of GBM cells, and their potential for sensitizing GBM cells to TMZ. Our findings show that MiR-329/449b treatments suppressed spheroid formation and migration of GBM (LN229 and U87) cells. When miR treatments were combined with Temozolomide (TMZ), we also observed that they synergistically enhanced the suppressive effects of TMZ and inhibited the activity of clinically significant NF-KB and Src/FAK signaling pathways, making the combination therapy a viable option to treat GBM, with greater impact on patient survival.
- 10 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26  (12) , 5533
Open AccessMiR 329/449 Suppresses Cell Proliferation, Migration and Synergistically Sensitizes GBM to TMZ by Inhibiting Src/FAK, NF-kB, and Cyclin D1 Activity
Glioblastoma Multiforme (GBM) is one of the most common brain tumors and is associated with aggressive tumor characteristics and extremely poor patient survival. The median survival time for GBM patients is around 12–15 months. Temozolomide (TMZ) is a key chemotherapeutic drug used in the treatment of GBM. However, at least 50% of GBM patients do not respond to TMZ, necessitating the identification of novel therapeutic strategies sensitizing patients to TMZ. In this study, we aimed to investigate the effects of two different tumor suppressor microRNAs (miR-329 and miR-449b) on cell proliferation and migration of GBM cells, and their potential for sensitizing GBM cells to TMZ. Our findings show that MiR-329/449b treatments suppressed spheroid formation and migration of GBM (LN229 and U87) cells. When miR treatments were combined with Temozolomide (TMZ), we also observed that they synergistically enhanced the suppressive effects of TMZ and inhibited the activity of clinically significant NF-KB and Src/FAK signaling pathways, making the combination therapy a viable option to treat GBM, with greater impact on patient survival.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85  (8_Suppleme) , 6
Abstract 6: Targeting eukaryotic elongation factor 2 kinase (eEF2K) to combat cancer stem cells and tumorigenesis in triple-negative breast cancer
Breast cancer remains the most commonly diagnosed cancer and the second leading cause of cancer-related deaths among women. Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers, is a highly aggressive and lethal form of breast cancer (BC) and characterized by the lack of ER, PR, and HER2 receptor expression, early relapses, drug resistance, and the poorest survival outcomes among all BC subtypes. Currently, there are no effective targeted therapies for TNBC, highlighting the urgent need for novel treatment strategies. eEF2K is an atypical alpha kinase that has been shown to promote TNBC cell proliferation, migration, invasion, and tumor growth. We previously validated eEF2K for the first time as a potential molecular target in TNBC and demonstrated that genetic inhibition of eEF2K completely suppresses in vivo TNBC tumor growth in mice. Overall data suggests that eEF2K is a critical oncogenic driver of TNBC tumorigenesis. Cancer stem cells (CSCs), a small but specific group of cancer cells, play a significant role in relapses and resistance to therapeutics including chemo-drugs. CSCs initiate tumor formation, promote tumor growth and cause relapses with their self-renewal and self-proliferation properties. While TNBC is known for the high number of CSCs population, the role of eEF2K in CSCs is unknown. In this study, we report the critical role of eEF2K in TNBC CSCs survival and tumorigenesis and found that the inhibition of eEF2K by siRNA and a small molecule inhibitor that we developed dramatically suppressed CSCs growth, migration, invasion and spheroid formation as well as TNBC cell proliferation and tumor growth in mice multiple TNBC models. Conversely, eEF2K overexpression promoted sphere formation. Our Kaplan-Meier analysis of the Cancer Genome Atlas (TCGA) revealed that high expression of eEF2K and ALDH1a3, a stemness marker, is associated with shorter overall and relapse-free survival. We also found that eEF2K is highly overexpressed in the ALDH-positive TNBC stem cell population. Genetic knockdown and pharmacological inhibition of eEF2K significantly suppressed the expression of key stemness signaling molecules, including ALDH1a3, Notch1, and Notch2. Currently, we are targeting eEF2K in MDA-MB-231 and MDA-MB-436 TNBC orthotopic xenograft and 4T1 mouse mammary tumor models in syngeneic mice to further assess its impact on CSCs-driven tumorigenesis. Our findings suggest that eEF2K plays a pivotal role in promoting TNBC stemness through the modulation of key stemness pathways, including ALDH1a3, Notch1, and Notch2 and tumor growth. Targeting eEF2K may therefore be a promising therapeutic strategy to eradicate TNBC by targeting primary and CSCs populations. Citation Format: Ezgi Biltekin, Nermin Kahraman, Yasemin M.Akay, Gulperi Oktem, Metin Akay, Bulent Ozpolat. Targeting eukaryotic elongation factor 2 kinase (eEF2K) to combat cancer stem cells and tumorigenesis in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85  (8_Suppleme) , 6
Abstract 6: Targeting eukaryotic elongation factor 2 kinase (eEF2K) to combat cancer stem cells and tumorigenesis in triple-negative breast cancer
Breast cancer remains the most commonly diagnosed cancer and the second leading cause of cancer-related deaths among women. Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers, is a highly aggressive and lethal form of breast cancer (BC) and characterized by the lack of ER, PR, and HER2 receptor expression, early relapses, drug resistance, and the poorest survival outcomes among all BC subtypes. Currently, there are no effective targeted therapies for TNBC, highlighting the urgent need for novel treatment strategies. eEF2K is an atypical alpha kinase that has been shown to promote TNBC cell proliferation, migration, invasion, and tumor growth. We previously validated eEF2K for the first time as a potential molecular target in TNBC and demonstrated that genetic inhibition of eEF2K completely suppresses in vivo TNBC tumor growth in mice. Overall data suggests that eEF2K is a critical oncogenic driver of TNBC tumorigenesis. Cancer stem cells (CSCs), a small but specific group of cancer cells, play a significant role in relapses and resistance to therapeutics including chemo-drugs. CSCs initiate tumor formation, promote tumor growth and cause relapses with their self-renewal and self-proliferation properties. While TNBC is known for the high number of CSCs population, the role of eEF2K in CSCs is unknown. In this study, we report the critical role of eEF2K in TNBC CSCs survival and tumorigenesis and found that the inhibition of eEF2K by siRNA and a small molecule inhibitor that we developed dramatically suppressed CSCs growth, migration, invasion and spheroid formation as well as TNBC cell proliferation and tumor growth in mice multiple TNBC models. Conversely, eEF2K overexpression promoted sphere formation. Our Kaplan-Meier analysis of the Cancer Genome Atlas (TCGA) revealed that high expression of eEF2K and ALDH1a3, a stemness marker, is associated with shorter overall and relapse-free survival. We also found that eEF2K is highly overexpressed in the ALDH-positive TNBC stem cell population. Genetic knockdown and pharmacological inhibition of eEF2K significantly suppressed the expression of key stemness signaling molecules, including ALDH1a3, Notch1, and Notch2. Currently, we are targeting eEF2K in MDA-MB-231 and MDA-MB-436 TNBC orthotopic xenograft and 4T1 mouse mammary tumor models in syngeneic mice to further assess its impact on CSCs-driven tumorigenesis. Our findings suggest that eEF2K plays a pivotal role in promoting TNBC stemness through the modulation of key stemness pathways, including ALDH1a3, Notch1, and Notch2 and tumor growth. Targeting eEF2K may therefore be a promising therapeutic strategy to eradicate TNBC by targeting primary and CSCs populations. Citation Format: Ezgi Biltekin, Nermin Kahraman, Yasemin M.Akay, Gulperi Oktem, Metin Akay, Bulent Ozpolat. Targeting eukaryotic elongation factor 2 kinase (eEF2K) to combat cancer stem cells and tumorigenesis in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85  (8_Suppleme) , 6953
Abstract 6953: Inhibition of Eukaryotic elongation factor 2 kinase (eEF2K) disrupts key processes in colorectal cancer progression and tumor growth
Colorectal cancer (CRC) is the third most commonly diagnosed cancer with 1.9 million new cases and the second leading cause of cancer-related deaths, with 935, 000 deaths reported in 2023. Despite advances in therapy, the 5-year survival rate for metastatic CRC remains as low as 14%, emphasizing the need for novel treatment strategies. Previously, we have validated that Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical alfa kinase as a potential molecular target that is commonly expressed in highly aggressive solid cancers such as triple-negative breast cancer, pancreatic, ovarian, and lung cancers and demonstrated that it acts as a key player in the survival, proliferation, invasion, and tumor growth of cancer cells and promoting cell. In this study, we investigated the role of eEF2K in colon cancer tumorigenesis and progression and its potential as a therapeutic target using a novel eEF2K small molecule inhibitor and siRNA-based knockdown studies. We found that eEF2K expression is highly expressed in CRC cell lines and eEF2K is associated with shorter patient survival and poor prognostic marker in CRC patients (NCI-TCGA patient database), inhibition of eEF2K in various CRC cell lines (HCT116, RKO, COLO320, and with different genetic alterations leads to suppression on cell proliferation, migration, and invasion. Western blot analysis confirmed that treatment with the siRNA and the eEF2K inhibitor reduced the activity of clinically significant signaling molecules including Src, FAK, and Cyclin D1 which are crucial for tumor growth and progression. In vivo, targeting of eEF2K by eEF2K siRNA encapsulated in iron oxide nanoparticles (IONPS) and our novel water soluble small-molecule eEF2K inhibitor suppressed CRC tumor growth of HTC116 and RKO tumors (flank) CRC tumor models in nude mice, with no observed toxicity. Analysis of tumor tissues by immunohistochemistry showed significant inhibition of the Ki-67 proliferation marker and induction of apoptosis by TUNEL staining. Our study provides the first evidence that eEF2K is a clinically significant potential molecular target and contributes to tumorigenesis and progression of CRC. Its effective inhibition is safe and can suppress tumor growth in preclinical CRC models. These promising results lay the foundation for further developing eEF2K-targeted therapies, offering a potential new approach for treating CRC. Citation Format: Nermin Kahraman, Ezgi Biltekin, Ogun Ali Gul, Goknur Kara, Izabela Fokt, M. Akay Yasemin, Waldemar Priebe, Metin Akay, Bulent Ozpolat. Inhibition of Eukaryotic elongation factor 2 kinase (eEF2K) disrupts key processes in colorectal cancer progression and tumor growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6953.
- 21 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85  (8_Suppleme) , 6953
Abstract 6953: Inhibition of Eukaryotic elongation factor 2 kinase (eEF2K) disrupts key processes in colorectal cancer progression and tumor growth
Colorectal cancer (CRC) is the third most commonly diagnosed cancer with 1.9 million new cases and the second leading cause of cancer-related deaths, with 935, 000 deaths reported in 2023. Despite advances in therapy, the 5-year survival rate for metastatic CRC remains as low as 14%, emphasizing the need for novel treatment strategies. Previously, we have validated that Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical alfa kinase as a potential molecular target that is commonly expressed in highly aggressive solid cancers such as triple-negative breast cancer, pancreatic, ovarian, and lung cancers and demonstrated that it acts as a key player in the survival, proliferation, invasion, and tumor growth of cancer cells and promoting cell. In this study, we investigated the role of eEF2K in colon cancer tumorigenesis and progression and its potential as a therapeutic target using a novel eEF2K small molecule inhibitor and siRNA-based knockdown studies. We found that eEF2K expression is highly expressed in CRC cell lines and eEF2K is associated with shorter patient survival and poor prognostic marker in CRC patients (NCI-TCGA patient database), inhibition of eEF2K in various CRC cell lines (HCT116, RKO, COLO320, and with different genetic alterations leads to suppression on cell proliferation, migration, and invasion. Western blot analysis confirmed that treatment with the siRNA and the eEF2K inhibitor reduced the activity of clinically significant signaling molecules including Src, FAK, and Cyclin D1 which are crucial for tumor growth and progression. In vivo, targeting of eEF2K by eEF2K siRNA encapsulated in iron oxide nanoparticles (IONPS) and our novel water soluble small-molecule eEF2K inhibitor suppressed CRC tumor growth of HTC116 and RKO tumors (flank) CRC tumor models in nude mice, with no observed toxicity. Analysis of tumor tissues by immunohistochemistry showed significant inhibition of the Ki-67 proliferation marker and induction of apoptosis by TUNEL staining. Our study provides the first evidence that eEF2K is a clinically significant potential molecular target and contributes to tumorigenesis and progression of CRC. Its effective inhibition is safe and can suppress tumor growth in preclinical CRC models. These promising results lay the foundation for further developing eEF2K-targeted therapies, offering a potential new approach for treating CRC. Citation Format: Nermin Kahraman, Ezgi Biltekin, Ogun Ali Gul, Goknur Kara, Izabela Fokt, M. Akay Yasemin, Waldemar Priebe, Metin Akay, Bulent Ozpolat. Inhibition of Eukaryotic elongation factor 2 kinase (eEF2K) disrupts key processes in colorectal cancer progression and tumor growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6953.